BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37792745)

  • 1. The Role of Interleukin 6 (IL6), Cancer Antigen-125 (CA-125), and Human Epididymis Protein 4 (HE4) to predict tumor resectability in the advanced epithelial ovarian cancer patients.
    Muhammad S; Azwan RJ; Rita RS; Susanti R; Yusrawati
    PLoS One; 2023; 18(10):e0292282. PubMed ID: 37792745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Epididymis Protein 4 (HE4) and Cancer Antigen 125 (CA125) for Prediction of Optimal Primary Surgery in Non-Mucinous Epithelial Ovarian Cancer.
    Promchit K; Oranratanaphan S
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):281-286. PubMed ID: 38285795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer.
    Innao P; Pothisuwan M; Pengsa P
    Asian Pac J Cancer Prev; 2016; 17(9):4483-4486. PubMed ID: 27797265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of serum human epididymis protein 4 in epithelial ovarian cancer and its correlation with prognosis].
    Zheng H; Gao YN; Gao WJ; Gao M; Yan X
    Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):445-9. PubMed ID: 24119905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
    Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
    Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.
    Chang X; Ye X; Dong L; Cheng H; Cheng Y; Zhu L; Liao Q; Zhao Y; Tian L; Fu T; Chen J; Cui H
    Int J Gynecol Cancer; 2011 Jul; 21(5):852-8. PubMed ID: 21633297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z; Tao X; Ying C
    Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
    Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
    Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Bendifallah S; Body G; Daraï E; Ouldamer L
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.